（标普500指数分时图，来源：Wind）After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high; Warren Buffett's deputy sold more than half of Berkshire Hathaway's holdings, pushing the stock price down for the seventh consecutive day; AirPods Pro has transformed into an OTC hearing aid, and FDA has approved Apple's hearing assistance software; Gilead's AIDS preventive drug once again delivered positive results.
According to Caixin, on September 13th, with the release of the latest US PPI data, all important data before the Fed's launch of the current round of interest rate cuts have been published. Just as the US stock market is preparing to enter the "waiting mode," OpenAI unexpectedly launched the "Strawberry" large model, leading to a wave of afternoon gains in the US stock market.
At the close, the S&P 500 index rose 0.75% to 5,595.76 points; the Nasdaq index rose 1% to 17,569.68 points; the Dow Jones Industrial Average rose 0.58% to 41,096.77 points.
(S&P 500 index hourly chart, source: Wind)
With the continuous rise of the Nasdaq and S&P for the fourth day, the S&P 500 index is now 1.3% away from its historical high of 5,669.67 points.
Of course, counting yesterday's speech by Huang Renxun, the tech giants have pushed the US stock market higher for two consecutive days. This also means that such days will not happen every day, and the market will ultimately return to reflecting the fundamentals.
Mona Mahajan, a senior investment strategist at Edward Jones, said that people usually adopt a wait-and-see attitude before the Fed meeting, and the US stock market will remain volatile in the traditionally weaker September. If the market continues to be in the background of Fed interest rate cuts and gradual easing of inflation, and eventually achieves a soft landing in the economy, historical data show that the market should continue to perform well in this situation.
On the other side of the Atlantic, the European Central Bank cut interest rates by another 25 basis points on Thursday as expected. Lagarde expects inflation to rise by the end of this year and then continue to decline next year. The European Central Bank also lowered its economic growth expectations for this year and the outlook for the next two years.
Hot stocks rose and fell.
On Thursday, the tech giants continued to maintain their momentum, with Apple up 0.05%, Microsoft up 0.94%, Amazon up 1.34%, Meta up 2.69%, Google-A up 2.34%, Tesla up 0.74%, Nvidia up 1.92%, and Intel down 1.43%.
Chinese concept stocks entered a mixed state of rise and fall, with the NASDAQ China Golden Dragon Index down 0.79%. Alibaba rose 0.80%, Baidu rose 0.14%, PDD Holdings rose 2.15%, JD.com rose 0.34%, NetEase fell 1.27%, NIO Inc fell 5.71%, Li Auto Inc fell 3.58%, and XPeng fell 5.69%.
Other news
[Buffett's deputy sells more than half of Berkshire's holdings]
Ajit Jain, Vice Chairman of Berkshire Hathaway and director-in-charge of insurance business, disclosed after the market closed yesterday that on September 9, he sold 200 shares of Berkshire Hathaway Class A shares at a price of $695,417.65, equivalent to cashing out $0.139 billion (approximately RMB 0.99 billion). Influenced by this news, Berkshire Hathaway A fell 0.69% on Thursday, marking the seventh consecutive trading day of decline.
After completing this transaction, Jain himself still holds 61 shares of Berkshire Hathaway Class A shares. In addition, his family trust holds 55 shares, and the non-profit organization Jain Foundation holds 50 shares.
[Gilead Sciences' AIDS prevention drug delivers positive results again]
The results announced by Gilead Sciences on Thursday showed that the new pre-exposure prophylaxis (PrEP) drug for HIV, lenacapavir, once again demonstrated high efficacy. Among the 2,180 participants in the lenacapavir group, there were only 2 new cases, and 99.9% of the participants were not infected with HIV, a relative risk reduction of 96%; in the control group of 1,087 participants, there were 9 new cases. As of the close on Thursday, Gilead Sciences' stock rose by 2.74%, approaching its historical high.
Eli Lilly and Co announced on Thursday that it will invest $1.8 billion to expand production capacity for its popular weight loss, diabetes, and Alzheimer's disease drugs at two production sites in Ireland.
Pharmaceutical giant Eli Lilly and Co announced on Thursday that it will invest $1.8 billion at two production sites in Ireland to promote the production of its popular weight loss, diabetes, and Alzheimer's disease drugs.
The U.S. FDA announced on Thursday that Apple's hearing assistive feature (HAF) has become the first over-the-counter (OTC) hearing assistive software in history. According to the FDA, after customization based on the user's hearing needs, AirPods Pro with this software installed will become an OTC hearing aid, amplifying sound for individuals with mild to moderate hearing loss over the age of 18.
The U.S. FDA announced on Thursday that Apple's hearing assistive feature (HAF) has become the first over-the-counter (OTC) hearing assistive software in history. According to the FDA, after customization based on the user's hearing needs, AirPods Pro with this software installed will become an OTC hearing aid, amplifying sound for individuals with mild to moderate hearing loss over the age of 18.
Moderna, the well-known mRNA industry company, announced on Thursday that it will cut its development budget by 20% over the next three years due to poor vaccine sales. Five projects in the pipeline will be terminated, and the goal of achieving a breakeven point will be postponed from 2026 to 2028. As a result, the company's stock price fell by 12.36%, hitting a new low for the year.
Moderna, the well-known mRNA industry company, announced on Thursday that it will cut its development budget by 20% over the next three years due to poor vaccine sales. Five projects in the pipeline will be terminated, and the goal of achieving a breakeven point will be postponed from 2026 to 2028. As a result, the company's stock price fell by 12.36%, hitting a new low for the year.
The company also announced that the mRNA vaccine for skin cancer developed in collaboration with Merck will be launched as early as next year.
Analysts downgrade Micron Technology's target price for the non-HBM memory market.
At the close, Micron Technology fell 3.79% on Thursday. Raymond James Financial analyst Srini Pajjuri lowered the company's target price from $160 to $125 due to a temporary slowdown in the non-HBM memory market. Pajjuri stated that PC/smartphone customers seem to have built up inventory ahead of price increases, which has resulted in a milder seasonal performance in the second half of 2024.
